Multiple Myeloma News & Features
Drug is now sanctioned for people who have received at least two prior standard therapies.
The FDA has approved Farydak (panobinostat) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.
Celgene received FDA approval to expand the indications for lenaliodomide (Revlimid) to include treatment of newly diagnosed multiple myeloma.
Magnetic resonance imaging (MRI) is gold standard for imaging axial skeleton, assessing painful lesions, and identification of benign fractures.
The molecular mail sent by multiple myeloma cells provides clues to how well patients with the disease are likely to respond to treatment, according to a study presented at ASH. The findings may ultimately guide doctors in deciding which therapies are best for individual patients with myeloma.
Multiple Myeloma Clinical Trials
- Women educated on overdiagnsosis are less likely to want mammogram
- New treatment method shrinks ovarian cancer tumors and improves chemotherapy effectiveness
- Novel drug approved for multiple myeloma
- New mechanism of acquired resistance to breast cancer drugs discovered
- Radiation therapy used most often for prostate cancer regardless of decision-making factors
- Patients with detectable PSA after prostatectomy should receive more aggressive radiation therapy
- Increase in brain tumors is not attributed to mobile phone use
- Black men have lower preference for investigation of prostate cancer
- ASCO: Active surveillance for prostate cancer may decrease survival odds for some
- Finding a qualified acupuncture practitioner
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|